

44th ANNUAL CONFERENCE

American Association of Bovine Practitioners St. Louis, Missouri September 22-24, 2011



"Vista[®] Once is going right back into the cooler and then it goes right back in the calves."

- Ray Pawlisch, DVM Wisconsi<mark>n</mark>

Vista[®] Once SQ is the most complete respiratory protection available, offering 5-way modified live viral protection in combination with the only avirulent-live culture Mannheimia haemolytica and Pasteurella multocida protection. And it's backed by respiratory research validating: • Respiratory duration of immunity of at least:

- <u>182 days for Infectious Bovine Rhinotracheitis</u> (IBR)
- 206 days for Bovine Virus Diarrhea (BVD) Type 1
- 200 days for BVD Type 2
- Three-day onset of immunity for IBR respiratory protection
- BVD Type 1b cross protection
- BVD Type 2 protection in the face of maternal antibodies

The five-way protection of Vista also is available in combination with the only single-dose *Lepto hardjo-bovis* protection: Vista 5 L5 SQ.

For more information about Vista vaccines, talk to your veterinarian or animal health provider.

Vista is property of Intervet International B.V. or affiliated companies or licensors and is protected by copyrights, trademark and other intellectual property laws. Copyright ©2011 Intervet International B.V. All rights reserved.



ISSN 0524-1685





EDITOR: ROBERT A. SMITH, DVM 3404 Live Oak Lane Stillwater, Oklahoma 74075 Tel: (405) 372-8666 Fax: (405) 743-8422

PUBLISHER:

VM PUBLISHING COMPANY

205 W. 7th Avenue, Suite 201G Stillwater, Oklahoma 74074 Tel/Fax: (405) 533-1883 kellijo.vmpubco@gmail.com

OFFICERS

President	
	Baton Rouge, Louisiana
President-Elect	Brian Gerloff, DVM
	Marengo, Illinois
Vice President	Nigel Cook, DVM
	Madison, Wisconsin
Past President	Roger Saltman, DVM
	Cazenovia, New York
Executive Vice President	M. Gatz Riddell, Jr., DVM
	Auburn, Alabama
Treasurer	Brian Reed, DVM 🐃
	Lititz, Pennsylvania
Parliamentarian	Rich Meiring, DVM
	Starkville, Mississippi

BOARD OF DIRECTORS

Mark J. Thomas, DVM Carthage, New York 1st District, 2011 Bob Cloninger, VMD Centre Hall, Pennsylvania 2nd District, 2012 James A. Brett, DVM Starkville, Mississippi 3rd District, 2013 Richard Wiley, DVM Wooster, Ohio 4th District, 2011 Glen Johnson, DVM Reedsburg, Wisconsin 5th District, 2012 Sarah Overby, DVM Freeport, Minnesota 6th District, 2013 Shawn Blood, DVM Guymon, Oklahoma 7th District, 2011 Glenn Rogers, DVM Aledo, Texas 8th District, 2012 David Rethorst, DVM Hastings, Nebraska 9th District, 2013 Steve Smalley, VMD Chandler, Arizona 10th District, 2011 Fred Muller, DVM Sunnyside, Washington 11th District, 2012

Vol. 45, No. 1

Spring 2011

Guy R. Boisclair, DVM Victoriaville, Quebec, Canada 12th District, 2013

J. Egan Brockhoff, DVM Olds, Alberta, Canada 13th District, 2011

AVMA DELEGATE:

EXHIBITS CHAIRMAN:

ADVERTISING AGENCY:

Mark Spire, DVM Manhattan, Kansas Charlie Hatcher, DVM College Grove, Tennessee J. T. O'Brien & Assoc. 12118 Nieman Road Overland Park, Kansas 66213 913-402-8383 Fax: 913-402-8384

THE BOVINE PRACTITIONER is published by The American Association of Bovine Practitioners, Inc., at VM Publishing Co., 205 W. 7th, Suite 201G, Stillwater, OK 74074 (Telephone and Fax: 405-533-1883). Over 6000 copies are mailed to veterinarians engaged in cattle practice and allied institutions. Send new address (please include old address) to: AABP, P.O. Box 3610, Auburn, AL 36831-3610

Tel: 1-800-269-2227; FAX 334-821-9532 e-mail: aabphq@aabp.org http://www.aabp.org

THE BOVINE PRACTITIONER is the official publication of The American Association of Bovine Practitioners, published in the spring and summer annually. It also serves as a communication medium between bovine practitioner organizations around the world. All manuscripts and communications must be presented in English.

Copies of THE BOVINE PRACTITIONER are available to non-members for \$25.00 per copy for domestic destinations, or \$33.00 for international addresses. Contact editor for details.

©American Association of Bovine Practitioners, 2011 • All Rights Reserved • The Bovine Practitioner • ISSN 0524-1685

Table of Contents

. 1
14
23
32
10
52
57
64
70
78
88

Advertisers Index


Addison Biological Laboratory, Inc	
Intervet/Schering-Plough Animal Health	inside front cover, front of book, 62, 63, inside back cover
Norbrook Labs	
Novartis Animal Health US, Inc.	
Pfizer Animal Health	

Cover photo courtesy of Dr. Keith Sterner, Ionia, Michigan.

The abstracts were translated to French by Dr. Guy Beauchamp and revised by Dr. Emile Bouchard.

Notice to Readers

All statements, opinions and conclusions contained in articles in *The Bovine Practitioner* are those of the author(s), and are not necessarily those of the American Association of Bovine Practitioners (AABP) unless specifically approved by the AABP Board of Directors.



RESFLOR GOLD is a broad-spectrum antibiotic that works against the four major bacterial causes of BRD and a non-steroidal anti-inflammatory drug in one.

Ask your Intervet/Schering-Plough Animal Health representative about RESFLOR GOLD.

Watch the video at www.resflorgold.com or scan the barcode to the right using your mobile device and the free app available at http://gettag.mobi



Time-tapse photos were taken of a randomly chosen call during an actual trial conducted at a Research Facility in Canyon, TX, on October 14, 2009. For subcutaneous use in beef and non-lactating dairy cattle only. Not for use in female dairy cattle 20 months of age or older or in calves to be processed for veal. The effects of florfenicol and flunixin on bovine reproductive performance, pregnancy, and lactation have not been determined. When administered according to the label directions, RESFLOR GOLD may induce a transient local reaction in the subcutaneous and underlying muscle tissue. Full product information on the following page. Resflor Gold is property of Intervet International B.V. or affiliated companies or licensors and is protected by copyrights, trademark and other intellectual property laws. Copyright © 2010 Intervet International B.V. All rights reserved. The correlation between *in vitro* susceptibility data and clinical effectiveness is unknown.⁴ Exhibits bactericidal activity against some strains of *Mannheimia haemolytica* and *Histophilus somni*. RES 418

PRODUCT INFORMATION

NADA 141-299, Approved by FDA.



(Florfenicol and Flunixin Meglumine) Antimicrobial/Non-Steroidal Anti-Inflammatory Drug

For subcutaneous use in beef and non-lactating dairy cattle only. Not for use in female dairy cattle 20 months of age or older or in calves to be processed for veal.

BRIEF SUMMARY: For full presribing information, see package insert.

INDICATION: RESFLOR GOLD[®] is indicated for treatment of bovine respiratory disease (BRD) associated with *Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and Mycoplasma bovis,* and control of BRD-associated pyrexia in beef and non-lactating dairy cattle.

CONTRAINDICATIONS: Do not use in animals that have shown hypersensitivity to florfenicol or flunixin.

WARNINGS: NOT FOR HUMAN USE. KEEP OUT OF REACH OF CHILDREN. This product contains material that can be irritating to skin and eyes. Avoid direct contact with skin, eyes, and clothing. In case of accidental eye exposure, flush with water for 15 minutes. In case of accidental skin exposure, wash with soap and water. Remove contaminated clothing. Consult a physician if irritation persists. Accidental injection of this product may cause local irritation. Consult a physician immediately. The Material Safety Data Sheet (MSDS) contains more detailed occupational safety information.

For customer service or to obtain a copy of the MSDS, call 1-800-211-3573. For technical assistance or to report suspected adverse reactions, call 1-800-219-9286.

Not for use in animals intended for breeding purposes. The effects of florfenicol on bovine reproductive performance, pregnancy, and lactation have not been determined. Toxicity studies in dogs, rats, and mice have associated the use of florfenicol with testicular degeneration and atrophy. NSAIDs are known to have potential effects on both parturition and the estrous cycle. There may be a delay in the onset of estrus if flunixin is administered during the prostaglandin phase of the estrous cycle. The effects of flunixin on imminent parturition have not been evaluated in a controlled study. NSAIDs are known to have the potential to delay parturition through a tocolytic effect.

RESFLOR GOLD®, when administered as directed, may induce a transient reaction at the site of injection and underlying tissues that may result in trim loss of edible tissue at slaughter.

RESIDUE WARNINGS: Animals intended for human consumption must not be slaughtered within 38 days of treatment. Do not use in female dairy cattle 20 months of age or older. Use of florfenicol in this class of cattle may cause milk residues. A withdrawal period has not been established in pre-ruminating calves. Do not use in calves to be processed for veal.

ADVERSE REACTIONS: Transient inappetence, diarrhea, decreased water consumption, and injection site swelling have been associated with the use of florfenicol in cattle. In addition, anaphylaxis and collapse have been reported post-approval with the use of another formulation of florfenicol in cattle.

In cattle, rare instances of anaphylactic-like reactions, some of which have been fatal, have been reported, primarily following intravenous use of flunixin meglumine.

Made in Germany Intervet Inc. Roseland, NJ 07068 ©2009, Intervet Inc. All Rights Reserved. Mav 2009 US 3448 IV